Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Determination of FXIIa Inhibition from US Patent US20240059691: "ENZYME INHIBITORS"
Assay data:275 Active, 166 Activity ≤ 1 µM, 340 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Inhibition of human fXIIA by fluorescence based analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of human fXIIa incubated for 1 hrs
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of human fXIIa using Z-GGR-AMC as substrate assessed as inhibition constant by fluorescence plate reader analysis
Assay data:3 Tested
Inhibition of human fXIIa using H-DPro-Phe-Arg-AFC as substrate
Inhibition of fXIIa (unknown origin)
Assay data:2 Tested
Biological Assay from US Patent US11584735: "Solid forms of a plasma kallikrein inhibitor and salts thereof"
SummaryRelated BioAssays by DepositorRelated BioAssays by Target
Inhibition of factor XIIa (unknown origin)
Inhibition of human factor 12a preincubated for 5 mins followed by substrate addition by fluorometer analysis
Inhibition of coagulation factor XIIa (unknown origin) assessed as chromogenic substrate using TH5253 as substrate at 1 mM incubated for 1 hr by spectrophotometer based microplate reader method
Inhibition of human factor 12a using H-D-Pro-Phe-Arg-p-nitroanilide as chromogenic substrate assessed as liberation of p-nitroaniline at 100 mM measured every 5 mins for 60 min by multimode plate reader analysis
Inhibition of human factor 12a using H-D-Pro-Phe-Arg-p-nitroanilide as chromogenic substrate assessed as liberation of p-nitroaniline at 2 mM measured every 5 mins for 60 min by multimode plate reader analysis
Inhibition of human factor 12a activation in citrated pooled human plasma assessed as inhibition of bradykinin release incubated for 10 mins followed by kaolin addition and measured after 15 mins by ELISA
Inhibition of human factor 12a using H-D-Pro-Phe-Arg-p-nitroanilide as chromogenic substrate assessed as liberation of p-nitroaniline in presence of BSA measured every 5 mins for 60 min by multimode plate reader analysis
Assay data:6 Active, 6 Activity ≤ 1 µM, 7 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human factor 12a using H-D-Pro-Phe-Arg-p-nitroanilide as chromogenic substrate assessed as liberation of p-nitroaniline measured every 5 mins for 60 min by multimode plate reader analysis
Assay data:57 Active, 50 Activity ≤ 1 µM, 87 Tested
Binding affinity to human coagulation factor 12a assessed as inhibition constant using H-D-Cyclohexylalanyl-glycyl-arginyl p-Nitroaniline as substrate measured upto 120 mins by spectrophotometric analysis
Factor XIIa (FXIIa) Inhibitory Activity from US Patent US11312723: "Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases"
Assay data:110 Active, 84 Activity ≤ 1 µM, 182 Tested
Determination of the % Inhibition for FXIIa from US Patent US11180484: "Pyrazole derivatives as plasma kallikrein inhibitors"
Assay data:54 Tested
Factor XIIa assay from US Patent US11014920: "Factor XIIa inhibitors"
Assay data:35 Active, 35 Activity ≤ 1 µM, 35 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Factor XIIa Assay from US Patent US10875851: "Factor XIIa inhibitors"
Assay data:174 Active, 17 Activity ≤ 1 nM, 174 Activity ≤ 1 µM, 174 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on